{"id":"W2979515484","doi":"10.1634/theoncologist.2019-0446","title":"De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Metastatic breast cancer; Hazard ratio; Internal medicine; Breast cancer; Pertuzumab; Clinical endpoint; Oncology; Proportional hazards model; Metastasis; Trastuzumab; Confidence interval; Cancer; Chemotherapy; Cancer registry; Progression-free survival; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004307107,0.0002089443,0.0004033241,0.00002033289,0.0001541741,0.00006695794,0.000226711,0.00006707442,0.0004533007],"category_scores_gemma":[0.0001383635,0.000107806,0.00008049235,0.0001192688,0.0004687792,0.00002968828,0.0001008986,0.0003322246,0.00008613988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001553391,"about_ca_system_score_gemma":0.0006325571,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01270134,"about_ca_topic_score_gemma":0.001323545,"domain_scores_codex":[0.9982873,0.0004341767,0.0002388752,0.0003305966,0.0003099093,0.0003991433],"domain_scores_gemma":[0.9978916,0.001097873,0.0001636227,0.0005901649,0.0001078528,0.0001488594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02363884,0.001762178,0.365192,0.0003115171,0.003106483,0.0006207976,0.01162179,0.00003186973,0.003309597,0.0007707463,0.01034046,0.5792937],"study_design_scores_gemma":[0.01309208,0.009863459,0.8610016,0.001082318,0.001604649,0.0003698096,0.01272623,0.0005864356,0.000946547,0.000123408,0.09796723,0.0006362979],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797112,0.00135828,0.000007056526,0.01238616,0.0009814736,0.00115003,0.001219292,0.00003706024,0.003149494],"genre_scores_gemma":[0.9965105,0.001710209,0.0000561029,0.0004393513,0.0003396144,0.0001752992,0.00006547668,0.00003060516,0.0006728252],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5786574,"threshold_uncertainty_score":0.9938732,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05891216506106133,"score_gpt":0.3761415138606755,"score_spread":0.3172293487996141,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}